LLVK (TFA)

LLVK TFA is a selective IκB phosphorylation inhibitor. LLVK TFA reduces LPS-induced pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) . LLVK TFA is promising for research of inflammatory bowel disease and rheumatoid arthritis[1].

12352209

IKK; NF-κB

NF-κB

Inflammation/Immunology

99.50

O=C(O)C(F)(F)F.O=C(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(O)=O)=O)=O)[C@H](CC(C)C)N

C25H46F3N5O7

585.66

[1]Liu W, et al. Alternation in sequence features and their influence on the anti-inflammatory activity of soy peptides during digestion and absorption in different enzymatic hydrolysis conditions. Food Chem. 2025 Apr 15;471:142824.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P11296A/LLVK-TFA-SDS-MedChemExpress.pdf

Peptides

No Development Reported